Zai Lab Limited Overview
Pro stress-test →Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious diseases. The company operates as a dual-engine model combining a commercially profitable and scaling China business with a global innovation engine.
Strategic Profile
Pro stress-test →The company's fully integrated cross-border R&D platform enables faster, more capital-efficient development of high-quality assets, as demonstrated by Zoci's rapid advancement from first-in-human studies to global pivotal trials. The China commercial business remains a key source of stability and funding for R&D, while the global oncology and immunology pipeline has reached a scale and maturity with a clear path toward the company's first potential U.S. approval by 2028.
Competitive Landscape
Pro stress-test →Zai Lab has strategic partnerships with industry giants including Tesaro Inc., NovoCure Ltd., Deciphera Pharmaceuticals, Paratek Bermuda Ltd., argenx SE., Bristol Myers Squibb, Mirati Therapeutics, Amgen Inc., Innoviva Inc., and Karuna Therapeutics. The company competes against multinational biopharmaceutical firms while leveraging its China commercial advantage to fund global R&D.
Industry Context
Zai Lab Limited operates in Biopharmaceutical - Oncology, Immunology, Neuroscience, Infectious Diseases.
Key facts
Founded: 2013 · Headquarters: Shanghai, China · Revenue: $460M · Market cap: $2.17B